The Focal Segmental Glomerulosclerosis (FSGS) drugs in development market research report provides comprehensive information on the therapeutics under development for Focal Segmental Glomerulosclerosis (FSGS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Focal Segmental Glomerulosclerosis (FSGS). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Focal Segmental Glomerulosclerosis (FSGS) and features dormant and discontinued products.
GlobalData tracks 24 drugs in development for Focal Segmental Glomerulosclerosis (FSGS) by 19 companies/universities/institutes. The top development phase for Focal Segmental Glomerulosclerosis (FSGS) is phase i with eight drugs in that stage. The Focal Segmental Glomerulosclerosis (FSGS) pipeline has 24 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Focal Segmental Glomerulosclerosis (FSGS) pipeline products market are: Delta 4, Sanofi and Vertex Pharmaceuticals.
The key targets in the Focal Segmental Glomerulosclerosis (FSGS) pipeline products market include Apolipoprotein L1, Endothelin 1 Receptor, and Short Transient Receptor Potential Channel 6.
The key mechanisms of action in the Focal Segmental Glomerulosclerosis (FSGS) pipeline product include Short Transient Receptor Potential Channel 6 Blocker with two drugs in Phase II. The Focal Segmental Glomerulosclerosis (FSGS) pipeline products include four routes of administration with the top ROA being Oral and three key molecule types in the Focal Segmental Glomerulosclerosis (FSGS) pipeline products market including Small Molecule, and Monoclonal Antibody.
Focal Segmental Glomerulosclerosis (FSGS) overview
Focal segmental glomerulosclerosis (FSGS) is a rare kidney disease that causes scarring of the glomeruli, the tiny filters that remove waste from the blood. The scarring affects only some parts of some glomeruli, hence the name “focal segmental”. FSGS can lead to protein loss in the urine, swelling in the body, high cholesterol, and kidney failure. FSGS can have different causes, such as infections, drugs, genetic mutations, or other kidney diseases. Sometimes, the cause is unknown. Treatment for FSGS depends on the type and severity of the disease. It may include medications to reduce proteinuria and blood pressure, dietary changes, dialysis, or kidney transplant.
For a complete picture of Focal Segmental Glomerulosclerosis (FSGS)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
